Bidding 24-27 Mar 2026, price band ₹372–392, lot 38 shares.
GMP last updated: 2 Apr 2026, 8:37 AM IST
| Date | GMP (₹) | Est. Listing Price (₹) | Est. Listing Gain |
|---|---|---|---|
| 4 Oct | ₹11 | ₹403 | 2.81% |
| 3 Oct | ₹32 | ₹424 | 8.16% |
| 2 Oct | ₹17 | ₹409 | 4.34% |
| 1 Oct | ₹10 | ₹402 | 2.55% |
| 30 Sep | ₹8 | ₹400 | 2.04% |
After allotment
| Category | Times | Est. Allotment Chances* |
|---|---|---|
| HNIs (Total) | 2.45 | 40.8% |
| bHNI | 3.56 | 28.1% |
| sHNI | 0.24 | 100% |
| QIBs | 1.73 | - |
| Retail | 0.12 | 100% |
| Total | 1.08 | - |
*Rough estimate: 1 ÷ times subscribed. Retail and HNI allotment is by lottery, so actual odds depend on the number of applications.
Sai Parenteral’s Limited is a diversified pharmaceutical formulations company incorporated in January 2001. It was originally established as a private limited company and was converted into a public limited company in January 2022. Anil Kumar Karusala, Vijitha Gorrepati and Karusala Aruna promote the Company. The Company operates across branded generic formulations and contract development and manufacturing (CDMO) services. Its product portfolio spans multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, antibiotics, gastroenterology, respiratory care, dermatology, and vitamins and supplements. Offerings cover a wide range of dosage forms such as injectables, tablets, capsules, liquid orals and ointments.